Oragenics Inc. Demonstrates Concussion Drug ONP-002 Designed for Acute Field Administration Is Stable Over a Wide Temperature Range Page 1

• ONP-002 stability eliminates the need for cumbersome cold storage
• No FDA-approved pharmaceutical treatment available for concussion

SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that its lead candidate for the treatment of concussion, ONP-002, is stable over a wide temperature range, eliminating the need for cumbersome cold storage for the drug and device combination. ONP-002 is a new chemical entity (NCE) designed to reach the brain via a breath-driven delivery system into the nasal cavity to treat concussions.